Knee osteoarthritis
Drug research and approvals for knee osteoarthritis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 402 studies of knee osteoarthritis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 402
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Periodontitis in Patients With OsteoarthritisNCT07935421 · Not reported · University of Zagreb · starts Jan 15, 2025
- Effects of Virtual Reality Environments on Walking in Adults With and Without Knee OsteoarthritisNCT07920120 · Not applicable · University of Primorska · starts Aug 26, 2026
- A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA…NCT07919678 · Phase 3 · Pfizer · starts Oct 26, 2026
- Study NRPT Feasibility in Knee OsteoarthritisNCT07917403 · Not applicable · University of California, San Diego · starts Dec 1, 2026
- A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With…NCT07915609 · Phase 3 · Pfizer · starts Oct 26, 2026
- The Effect of Different Exercise Training Programs on Muscle Oxygenation in Individuals With Knee OsteoarthritisNCT07904741 · Not applicable · Bahçeşehir University · starts Oct 20, 2026
- A Single-Center Phase 1 Study of ceAF for Knee Osteoarthritis (KOA)NCT07902128 · Phase 1 · Anhui HygeianCells BioMedical Co., Ltd. · starts Dec 10, 2025
- Autologous Adipose-Derived Stem Cell Injections for Knee OsteoarthritisNCT07901790 · Not applicable · Yonsei University · starts Sep 3, 2026
- SVF Cellular Composition, Secretome, and Responses in Knee OsteoarthritisNCT07898501 · Not reported · Yonsei University · starts Nov 1, 2026
Phase 3 12 of 40
- CelecoxibCyclooxygenase-2 inhibitor
- Triamcinolone acetonideGlucocorticoid receptor agonist
- DiclofenacCyclooxygenase inhibitor
- NaproxenCyclooxygenase inhibitor
- FasinumabBeta-nerve growth factor inhibitor
- LorecivivintDual specificity tyrosine-phosphorylation-regulated kinase 1A inhibitor
- LidocaineSodium channel alpha subunit blocker
- CapsaicinVanilloid receptor opener
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
- Hylan g-f 20Lubricant and shock absorber
- AcetaminophenCyclooxygenase inhibitor
- BupivacaineSodium channel protein type IV alpha subunit blocker
Phase 2 12 of 50
- OxytocinOxytocin receptor agonist
- Interleukin-10
- SAR-113945Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor
- Sprifermin
- MorphineMu opioid receptor agonist
- SomatropinGrowth hormone receptor agonist
- TriamcinoloneGlucocorticoid receptor agonist
- FasitibantBradykinin B2 receptor antagonist
- CebranopadolNociceptin receptor agonist
- Eptotermin alfaBone morphogenetic protein receptor type-1A agonist
- Dextrose
- Cannabinol
Phase 1 or earlier 12 of 17
- Fisetin
- IbuprofenCyclooxygenase inhibitor
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- Imrecoxib
- LosartanType-1 angiotensin II receptor antagonist
- WarfarinVitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- Ethiodized oilDiagnostic agent
- DexamethasoneGlucocorticoid receptor agonist
- Cortisone
- VerapamilVoltage-gated L-type calcium channel blocker
- TetracaineSodium channel alpha subunit blocker
- MavatrepVanilloid receptor antagonist
How its trials ended
2,972 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 517 whose ending is known, 51% met their primary endpoint, 8% missed it and 41% stopped early.
- Completed, result not reported1,34545%
- Ongoing62721%
- Status unknown48316%
- Met its primary endpoint2639%
- Stopped: other or unclear1334%
- Missed its primary endpoint421%
- Stopped: enrollment or feasibility331%
- Stopped: sponsor or business decision251%
- Stopped: funding9<1%
- Stopped: lack of efficacy8<1%
- Stopped: safety4<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA